| Biomarker ID | 984 |
| PMID | 22977195 |
| Year | 2012 |
| Biomarker | PTEN |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Overexpressed for Progression Free Survival |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways include: Immune system, Disease, T cell receptor regulation of apoptosis, Adaptive immune system, TGF-beta regulation of extracellular matrix |
| Experiment | Progression Free Survival |
| Type of Biomarker | Prognostic |
| Cohort | Patients with mCRPC progressing during or within 90 days after at least 12 weeks of docetaxel were included in this phase II trial. 27 patients were avaliable for IHC analysis. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p= 0.02 |
| Method Used | Immunohistochemistry |
| Clinical | Yes |
| Remarks | PFS was defined as the absence of disease progression for biochemical PSA progression |
| Clinical Trial Number | NCT00728663 |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |